Hostname: page-component-7b7567c8c-z4zkx Total loading time: 0 Render date: 2026-11-18T03:06:29.493Z Has data issue: false hasContentIssue false

Surrogate Endpoints and Drug Regulation: What Is Needed to Clarify the Evidence

Published online by Cambridge University Press:  01 January 2021

Rights & Permissions [Opens in a new window]

Abstract

The FDA's new table of surrogate endpoints used for drug approvals is an important step forward for overseeing the use of biomarkers in clinical trials. Nevertheless, we present several ways in which the table can be improved.

Information

Type
Symposium Articles
Copyright
Copyright © American Society of Law, Medicine and Ethics 2019
Figure 0

Table 1Extracted from the FDA's Tables of Surrogate Endpoints Used for Drug Approval

Figure 1

Table 2Survey of Cochrane Reviews Involving FEV1 and Asthma

Figure 2

Table 3Primary and FEV1 Outcomes in Cochrane Reviews Involving FEV1 and Asthma

Figure 3

Table 4Outcome Matrix for Survey of Cochrane Reviews Studying FEV1 and Clinical Endpoints in Asthma

Figure 4

Table 5Revised Row of FDA Table of Surrogate Endpoints for FEV1 in Adults with Asthma